AGIO
NASDAQ
US
Agios Pharmaceuticals, Inc. - Common Stock
$35.20
▲ +$1.01
(+2.95%)
Vol 1.4M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.6B
ROE
-28.3%
Margin
-895.9%
D/E
0.00
Beta
0.92
52W
$22–$46
Wall Street Consensus
16 analysts · Apr 20265
Strong Buy
7
Buy
4
Hold
0
Sell
0
Strong Sell
75.0%
Buy Rating
Price Chart
Similar Stocks
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
SLNO
Soleno Therapeutics Inc
$2.5B
STOK
Stoke Therapeutics Inc
P/E 44.2
$1.8B
VRDN
Viridian Therapeutics Inc
$3.0B
CAPR
Capricor Therapeutics Inc
$1.6B
SION
Sionna Therapeutics Inc
$1.8B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.99 | $-1.86 | +$0.13 |
| Sep 2025 | $-1.94 | $-1.78 | +$0.16 |
| Jun 2025 | $-1.84 | $-1.93 | $-0.09 |
| Mar 2025 | $-1.82 | $-1.55 | +$0.27 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $10.7M | $8.7M | $12.5M | $12.9M | $20.0M |
| Net Income | — | -$96.5M | -$89.3M | -$112.0M | -$103.4M | -$108.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 43.3% | 43.3% | 43.3% | -28.3% | -28.3% | -28.3% |
| P/E (TTM) | 2.96 | 3.24 | 3.59 | — | — | — |
| Net Margin | -899.4% | 1590.4% | 1590.4% | -895.9% | -895.9% | -895.9% |
| Gross Margin | 86.3% | 88.2% | 88.2% | 87.2% | 87.2% | 87.2% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 14.48 | 14.48 | 14.48 | 13.82 | 13.82 | 13.82 |
Key Ratios
ROA (TTM)
-26.4%
P/S (TTM)
35.44
P/B
1.2
EPS (TTM)
$-6.96
CF/Share
$-3.84
Rev Growth 3Y
-27.2%
52W High
$46.00
52W Low
$22.24
$22.24
52-Week Range
$46.00
Financial Health
Free Cash Flow
-$97.3M
Net Debt
-$48.9M
Cash
$89.1M
Total Debt
$40.2M
As of Dec 31, 2025
How does AGIO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
AGIO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
35.4
▲
176%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.2
▼
51%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
AGIO profitability vs Biotechnology peers
ROE
-28.4%
▲
58%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-895.9%
▼
212%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
87.2%
▲
11%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-26.4%
▲
43%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
AGIO financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
13.8
▲
211%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.9
▼
5%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
AGIO fundamentals radar
AGIO
Peer median
Industry
AGIO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio